Cancer Family
Malignant Thoracic Neoplasm
CI-CAN-00000256Explore in graph →
2,775 active trials51 approved drugs626 evidence items
- NCIt
- C3576
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000256Explore in graph →
Clinical trials
11,499 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,528)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03452150 | D-0316 First Time in Patients Ascending Dose Study | completed | Phase 1 | 84 | InventisBio Co., LtdINDUSTRY | 1 | Apr 25, 2023 | clinicaltrials |
| NCT03758781 | IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors | completed | Phase 1 | 12 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 14, 2023 | clinicaltrials |
| NCT05800418 |
| Clinical Study to Compare the Pharmacokinetics and Safety of Ramucirumab Injection With Cyramza ® in Healthy Male Volunteers |
| completed |
| Phase 1 |
| 88 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY |
| 1 |
| Apr 5, 2023 |
| clinicaltrials |
| NCT03849469 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors(DUET-4) | completed | Phase 1 | 78 | Xencor, Inc.INDUSTRY | 1 | Mar 30, 2023 | clinicaltrials |
| NCT01570296 | A Trial of Gefitinib in Combination With BKM120 in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFR(BKM120) | completed | Phase 1 | 38 | National Cancer Centre, SingaporeOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT03775850 | A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors | completed | Phase 1 | 69 | Evelo Biosciences, Inc.INDUSTRY | 2 | Mar 24, 2023 | clinicaltrials |
| NCT02503358 | Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer | completed | Phase 1 | 23 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 21, 2023 | clinicaltrials |
| NCT04323657 | TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 6 | TCR2 TherapeuticsINDUSTRY | 1 | Mar 16, 2023 | clinicaltrials |
| NCT04837677 | A Study of PRT1419 in Patients With Advanced Solid Tumors | completed | Phase 1 | 26 | Prelude TherapeuticsINDUSTRY | 1 | Mar 15, 2023 | clinicaltrials |
| NCT02983045 | A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors(PIVOT-02) | completed | Phase 1 / Phase 2 | 557 | Nektar TherapeuticsINDUSTRY | 8 | Mar 13, 2023 | clinicaltrials |
| NCT03689192 | Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors | completed | Phase 1 | 13 | Herlev HospitalOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT04177290 | A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC Patients | completed | Phase 1 | 48 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Feb 27, 2023 | clinicaltrials |
| NCT04672928 | A Phase Ib/III Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above Chemotherapies | completed | Phase 1 | 20 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Feb 27, 2023 | clinicaltrials |
| NCT05118334 | IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC) | completed | Phase 1 | 30 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Feb 23, 2023 | clinicaltrials |
| NCT01146756 | MEK Inhibitor and Thoracic Radiotherapy Trial(MEKRT) | completed | Phase 1 | 21 | The Christie NHS Foundation TrustOTHER | 1 | Feb 15, 2023 | clinicaltrials |
| NCT03463525 | Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases(ODIN-BM) | completed | Phase 1 | 4 | AstraZenecaINDUSTRY | 1 | Jan 27, 2023 | clinicaltrials |
| NCT02120807 | Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas | completed | Phase 1 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT02713529 | Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer | completed | Phase 1 / Phase 2 | 117 | AmMax Bio, Inc.INDUSTRY | 6 | Jan 20, 2023 | clinicaltrials |
| NCT01859026 | A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation | completed | Phase 1 | 43 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT04430842 | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | completed | Phase 1 | 15 | Quadriga Biosciences, Inc.INDUSTRY | 1 | Jan 18, 2023 | clinicaltrials |
| NCT04444427 | Evaluation of GLR2007 for Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 19 | Gan and Lee Pharmaceuticals, USAINDUSTRY | 1 | Dec 23, 2022 | clinicaltrials |
| NCT01177397 | Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma | completed | Phase 1 / Phase 2 | 226 | CelgeneINDUSTRY | 4 | Dec 13, 2022 | clinicaltrials |
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors(DUET-2) | completed | Phase 1 | 150 | Xencor, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT05631678 | Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or Itraconazole | completed | Phase 1 | 48 | Jiangsu Aosaikang Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 30, 2022 | clinicaltrials |
| NCT03360929 | Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759 | completed | Phase 1 / Phase 2 | 15 | LYZZ Alpha Holding LtdINDUSTRY | 1 | Nov 25, 2022 | clinicaltrials |
| NCT02857270 | A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer | completed | Phase 1 | 210 | Eli Lilly and CompanyINDUSTRY | 4 | Nov 22, 2022 | clinicaltrials |
| NCT02555007 | Metronomic Chemotherapy Based on Adaptative Bio-mathematical Model of Oral Vinorelbine in Patients With NSCLC or MPM(NVB Metro) | completed | Phase 1 | 30 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT02908750 | Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC | completed | Phase 1 | 24 | AstraZenecaINDUSTRY | 3 | Nov 14, 2022 | clinicaltrials |
| NCT01982955 | Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT) | completed | Phase 1 / Phase 2 | 88 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 7 | Nov 8, 2022 | clinicaltrials |
| NCT02039674 | A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) | completed | Phase 1 / Phase 2 | 267 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 8, 2022 | clinicaltrials |
| NCT03019666 | Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL | completed | Phase 1 | 39 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT00890617 | Cryotherapy in Treating Patients With Primary Stage I Non-Small Cell Lung Cancer or Lung Metastasis | completed | Phase 1 | 9 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT00652574 | Dasatinib in Resectable Malignant Pleural Mesothelioma | completed | Phase 1 | 56 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2022 | clinicaltrials |
| NCT02835690 | Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab (MK-3475) in Chinese Participants With Non-Small-Cell Lung Cancer (MK-3475-032/KEYNOTE-032) | completed | Phase 1 | 44 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Oct 26, 2022 | clinicaltrials |
| NCT00199849 | NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine | completed | Phase 1 | 18 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 10, 2022 | clinicaltrials |
| NCT02898116 | Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 2 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 10, 2022 | clinicaltrials |
| NCT03164772 | Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC | completed | Phase 1 / Phase 2 | 61 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 10, 2022 | clinicaltrials |
| NCT02310464 | Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects | completed | Phase 1 | 25 | OBI Pharma, IncINDUSTRY | 1 | Oct 3, 2022 | clinicaltrials |
| NCT03965845 | A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 53 | Calithera Biosciences, IncINDUSTRY | 1 | Sep 19, 2022 | clinicaltrials |
| NCT00602030 | Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC | completed | Phase 1 / Phase 2 | 141 | Syndax PharmaceuticalsINDUSTRY | 1 | Aug 22, 2022 | clinicaltrials |
| NCT02862457 | Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434) | completed | Phase 1 | 34 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 19, 2022 | clinicaltrials |
| NCT02404441 | Phase I/II Study of PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 319 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 3, 2022 | clinicaltrials |
| NCT03438318 | Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer | completed | Phase 1 | 29 | Regeneron PharmaceuticalsINDUSTRY | 1 | Aug 3, 2022 | clinicaltrials |
| NCT05476341 | A Phase I Clinical Trial of Bevacizumab Injection | completed | Phase 1 | 98 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 27, 2022 | clinicaltrials |
| NCT02926768 | Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors | completed | Phase 1 | 136 | Checkpoint Therapeutics, Inc.INDUSTRY | 5 | Jul 26, 2022 | clinicaltrials |
| NCT01014598 | Cisplatin in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer or Lung Metastasis | completed | Phase 1 | 11 | Roswell Park Cancer InstituteOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT03297424 | A Study of PLX2853 in Advanced Malignancies. | completed | Phase 1 | 49 | Opna Bio LLCINDUSTRY | 1 | Jul 25, 2022 | clinicaltrials |
| NCT01854684 | Photodynamic Therapy During Surgery in Treating Patients With Non-small Cell Lung Cancer That Can Be Removed by Surgery | completed | Phase 1 | 8 | Roswell Park Cancer InstituteOTHER | 1 | Jul 22, 2022 | clinicaltrials |
| NCT02071862 | Study of the Glutaminase Inhibitor CB-839 in Solid Tumors | completed | Phase 1 | 210 | Calithera Biosciences, IncINDUSTRY | 1 | Jul 20, 2022 | clinicaltrials |
| NCT03080311 | A Study of APG-1252 in Patients With SCLC or Other Solid Tumors | completed | Phase 1 | 50 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Apr 25, 2023source: clinicaltrials